Targeted delivery of platinum-based anticancer complexes

225Citations
Citations of this article
245Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The most widely used anticancer drugs are platinum-based. Their efficacy might be improved by carriers which can transport large numbers of Pt centres, shield the drug from premature activation, and/or deliver Pt specifically to cancer cells using vectors which recognise specific targets. We describe recent progress using functionalized carbon nanotubes (CNTs) and nanorods, hollow Prussian blue (HPB), magnetic iron oxide and gold nanoparticles, liposomes, nanogels and polymers, as well as active targeting by conjugation to biodegradable proteins and peptides (e.g. EGF, heparin, herceptin, somatostatin and TAT). Spatially targeted activation of PtIV prodrugs using light is also a promising approach. Interestingly, use of these new delivery and targeting systems for platinum drugs can lead to species with unusual reactivity which can kill cancer cells by new mechanisms. © 2013 Elsevier Ltd.

Cite

CITATION STYLE

APA

Butler, J. S., & Sadler, P. J. (2013, April). Targeted delivery of platinum-based anticancer complexes. Current Opinion in Chemical Biology. https://doi.org/10.1016/j.cbpa.2013.01.004

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free